Hefei Lifeon Pharmaceutical (003020)
- 17.26
- +0.31+1.83%
003020 Stock Chart
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
003020 Orderflow
003020 Orderflow Trend
No Data
Hefei Lifeon Pharmaceutical (003020) News
Lifang Pharmaceutical (003020.SZ): Received approval notice for the marketing application of dexmethylphenidate hydrochloride active pharmaceutical ingredient
Gelonghui, September 21 — LIFANG Pharmaceutical (003020.SZ) announced that it has received the "Approval Notice for the Marketing Application of Methylphenidate Hydrochloride API" from the National
Day One of the 2026 National Reimbursement Drug List Negotiations: Representatives from Multiple Companies Display Visible Joy as Traditional Chinese Medicine and Chronic Disease Drugs Take Center Stage
The annual national medical insurance catalog negotiations have once again entered the stage of on-site bargaining.
Cube Pharmaceutical: Semi-Annual Report for 2026
Cube Pharmaceutical: Summary of the 2026 Semi-Annual Report
Lifang Pharmaceutical (003020.SZ): Net profit for the first half of the year reached RMB 88.2051 million, a year-on-year decrease of 2.24%.
Gelong Hui, August 28 | Lifang Pharmaceutical (003020.SZ) announced its semi-annual report. During the reporting period, the company achieved total operating revenue of RMB 684.2596 million, a year-on-year decrease of 6.58%, and net profit attributable to owners of the parent company of RMB 88.2051 million, a year-on-year decrease of 2.24%. The methylphenidate hydrochloride extended-release tablets, formulated as a three-layer core osmotic pump preparation involving highly complex manufacturing processes, have achieved a significant breakthrough. Their approval for market launch demonstrates the company's industrialization capabilities in the field of complex osmotic pump technologies. The company will remain committed to the development of osmotic pump preparations with high technical barriers, leveraging its long-accumulated and established industrialization technologies to enhance its competitive edge.
Express News | Innovative drug concept stocks rebound amid volatility; Yuheng Pharmaceutical hits limit up five times in seven trading days
Shares in the innovative drug sector rebounded intraday amid volatility. Yuheng Pharmaceutical hit the daily price limit five times over seven trading days, while Huasen Pharmaceutical recorded two consecutive limit-ups. Longshen Rongfa, Tailong Pharmaceutical, Lifang Pharmaceutical, Ruikang Medicine, and CSPC Innovation were among the top gainers. On the news front, the value of outbound licensing (License-out) deals for Chinese innovative drugs surpassed USD 110 billion in the first half of 2026, accounting for eight of the global top ten transactions. The industry is transitioning from a phase of "selling narratives" to a new stage where pricing is driven by clinical data and commercialization capabilities.